

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
FEBRUARY 6, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Tribute Pharmaceuticals Canada Inc.**

**File No. 000-31198 - CF#31648**

---

Tribute Pharmaceuticals Canada Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on October 8, 2014, as amended.

Based on representations by Tribute Pharmaceuticals Canada Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 2.1	through	October 8, 2017
Exhibit 2.2	through	October 8, 2024

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary